Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Here, six house and techno artists provide a look into what it’s like being a tastemaker spinning at Time Warp. They discuss their favorite memories, why the event is special to them and more.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

The guidance predicts sales growth of 32% for the year, and the management team ... Eli Lilly has a first-mover advantage and the supply to feed the massive demand for weight-loss drugs. So, one ...